[Molecular targeted drugs in the developmental stage: 2) Various molecular targets and therapeutic agents under investigation].
Akita
Hirotoshi
H
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use; D016503:Drug Delivery Systems; D004351:Drug Resistance; D066246:ErbB Receptors; D006801:Humans; D000077341:Lapatinib; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D000077157:Sorafenib; D042442:Vascular Endothelial Growth Factors
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D011799:Quinazolines; D042442:Vascular Endothelial Growth Factors; D000077341:Lapatinib; D009536:Niacinamide; D000077157:Sorafenib; D066246:ErbB Receptors